Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
The FDA has approved three new treatment options for ESR1-mutated, ER-positive, HER2-negative advanced breast cancer in quick succession. Wilserdly (giredestrant) plus everolimus, imlunestrant (Inluriyo) plus abemaciclib, and camizestrant (Etcamah) plus a CDK4/6 inhibitor each target ESR1 mutations — a key driver of endocrine therapy resistance — offering oncologists a growing toolkit to combat this challenging disease.
The FDA has approved three distinct targeted regimens for ESR1-mutated, ER-positive, HER2-negative advanced breast cancer within months of each other, marking a significant shift in how oncologists can address endocrine therapy resistance.
Most recently, Wilserdly (giredestrant) plus everolimus received full approval (November 2026) for patients whose disease progressed on prior endocrine-based therapy. In the phase 3 evERA trial, the all-oral regimen cut the risk of disease progression or death by 62% vs. standard endocrine therapy plus everolimus in ESR1-mutated patients (median PFS: 10.0 vs. 5.5 months). Earlier, imlunestrant (Inluriyo) plus abemaciclib was approved (September 2026) for patients progressing after at least one line of endocrine therapy, based on EMBER-3 data showing a median PFS of 11.1 vs. 5.5 months with imlunestrant alone. And camizestrant (Etcamah) plus a CDK4/6 inhibitor received accelerated approval (September 2026) for a novel earlier-intervention strategy — switching therapy upon ctDNA detection of an ESR1 mutation before radiographic progression, with a median PFS of 16.0 vs. 9.2 months in SERENA-6.
By the Numbers:
Why it matters: ESR1 mutations emerge in roughly 30–50% of patients on aromatase inhibitor-based therapy and drive resistance — yet until recently, options were limited. These three approvals give clinicians multiple genomically guided strategies at different points in the treatment journey, from early ctDNA-detected mutation switching to post-progression salvage, fundamentally reshaping the management of advanced HR+ breast cancer.